Cargando…
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
CD8(+) T cell reactivity towards tumor mutation-derived neoantigens is widely believed to facilitate the antitumor immunity induced by immune checkpoint blockade (ICB). Here we show that broadening in the number of neoantigen-reactive CD8(+) T cell (NART) populations between pre-treatment to 3-weeks...
Autores principales: | Holm, Jeppe Sejerø, Funt, Samuel A., Borch, Annie, Munk, Kamilla Kjærgaard, Bjerregaard, Anne-Mette, Reading, James L., Maher, Colleen, Regazzi, Ashley, Wong, Phillip, Al-Ahmadie, Hikmat, Iyer, Gopa, Tamhane, Tripti, Bentzen, Amalie Kai, Herschend, Nana Overgaard, De Wolf, Susan, Snyder, Alexandra, Merghoub, Taha, Wolchok, Jedd D., Nielsen, Morten, Rosenberg, Jonathan E., Bajorin, Dean F., Hadrup, Sine Reker |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001725/ https://www.ncbi.nlm.nih.gov/pubmed/35410325 http://dx.doi.org/10.1038/s41467-022-29342-0 |
Ejemplares similares
-
Neoantigen-reactive CD8(+) T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
por: Kristensen, Nikolaj Pagh, et al.
Publicado: (2022) -
Evolution of MHC-based technologies used for detection of antigen-responsive T cells
por: Bentzen, Amalie Kai, et al.
Publicado: (2017) -
T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation
por: Bentzen, Amalie Kai, et al.
Publicado: (2019) -
CD8(+) T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens
por: Pedersen, Natasja Wulff, et al.
Publicado: (2019) -
Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8(+) T cell immunity in CLL and MDS patients
por: Hernandez, Susana Patricia Amaya, et al.
Publicado: (2023)